Alpha DNA Investment Management LLC Buys 159 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Alpha DNA Investment Management LLC grew its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 481.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 192 shares of the company’s stock after purchasing an additional 159 shares during the quarter. Alpha DNA Investment Management LLC’s holdings in 10x Genomics were worth $34,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in TXG. Harvard Management Co. Inc. bought a new position in shares of 10x Genomics in the 1st quarter worth about $16,195,000. State of New Jersey Common Pension Fund D lifted its stake in 10x Genomics by 108.8% in the first quarter. State of New Jersey Common Pension Fund D now owns 39,666 shares of the company’s stock valued at $7,180,000 after buying an additional 20,666 shares during the period. Jaffetilchin Investment Partners LLC boosted its holdings in shares of 10x Genomics by 11.4% during the 1st quarter. Jaffetilchin Investment Partners LLC now owns 7,403 shares of the company’s stock worth $1,340,000 after buying an additional 760 shares in the last quarter. Federated Hermes Inc. grew its position in shares of 10x Genomics by 404.4% during the 4th quarter. Federated Hermes Inc. now owns 50,662 shares of the company’s stock worth $7,174,000 after buying an additional 40,618 shares during the period. Finally, Vigilant Capital Management LLC bought a new stake in shares of 10x Genomics in the 1st quarter valued at $10,424,000. Hedge funds and other institutional investors own 68.71% of the company’s stock.

In other 10x Genomics news, insider Benjamin J. Hindson sold 41,666 shares of the firm’s stock in a transaction on Thursday, April 1st. The stock was sold at an average price of $184.54, for a total value of $7,689,043.64. Following the completion of the sale, the insider now directly owns 78,302 shares of the company’s stock, valued at $14,449,851.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John R. Stuelpnagel sold 7,500 shares of the business’s stock in a transaction on Wednesday, March 17th. The shares were sold at an average price of $169.36, for a total value of $1,270,200.00. Following the completion of the sale, the director now owns 450,291 shares in the company, valued at $76,261,283.76. The disclosure for this sale can be found here. Insiders sold a total of 225,735 shares of company stock worth $41,012,656 over the last three months. 11.57% of the stock is owned by insiders.

TXG has been the subject of several research analyst reports. Morgan Stanley lifted their price target on shares of 10x Genomics from $145.00 to $215.00 and gave the company an “overweight” rating in a research note on Thursday, February 25th. Citigroup increased their price target on 10x Genomics from $195.00 to $240.00 in a report on Thursday, February 18th. Zacks Investment Research upgraded 10x Genomics from a “sell” rating to a “hold” rating in a report on Thursday, March 25th. Cowen increased their target price on 10x Genomics from $155.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, February 18th. Finally, William Blair began coverage on shares of 10x Genomics in a research note on Monday, March 15th. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $183.70.

Shares of NASDAQ TXG opened at $191.16 on Friday. The stock has a market cap of $20.99 billion, a P/E ratio of -37.93 and a beta of 1.26. The business has a 50 day simple moving average of $176.92. 10x Genomics, Inc. has a twelve month low of $80.90 and a twelve month high of $203.25.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Tuesday, May 4th. The company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.16. 10x Genomics had a negative return on equity of 13.90% and a negative net margin of 160.22%. The business had revenue of $105.82 million for the quarter, compared to analyst estimates of $102.75 million. As a group, research analysts anticipate that 10x Genomics, Inc. will post -0.75 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Read More: What causes a recession?

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.